IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $418,840,632 | +8.8% | 9,233,700 | -1.6% | 6.75% | +22.9% |
Q2 2023 | $384,873,709 | +13.2% | 9,380,300 | -1.4% | 5.49% | +11.3% |
Q1 2023 | $339,955,306 | -7.6% | 9,511,900 | -2.4% | 4.93% | +1.0% |
Q4 2022 | $368,027,103 | -12.1% | 9,743,900 | +3.0% | 4.88% | -18.7% |
Q3 2022 | $418,566,000 | +15.6% | 9,463,400 | -3.2% | 6.01% | +17.4% |
Q2 2022 | $361,927,000 | -1.5% | 9,776,528 | -1.4% | 5.12% | +19.9% |
Q1 2022 | $367,365,000 | +16.6% | 9,918,073 | -4.2% | 4.27% | +31.3% |
Q4 2021 | $315,106,000 | +0.5% | 10,355,123 | +10.8% | 3.25% | +2.1% |
Q3 2021 | $313,529,000 | -20.8% | 9,347,926 | -5.9% | 3.18% | -17.7% |
Q2 2021 | $396,117,000 | -1.9% | 9,930,245 | +10.5% | 3.87% | -9.5% |
Q1 2021 | $403,932,000 | -21.1% | 8,984,234 | -0.7% | 4.27% | -27.1% |
Q4 2020 | $511,693,000 | +23.7% | 9,050,092 | +3.8% | 5.86% | +2.5% |
Q3 2020 | $413,588,000 | -15.0% | 8,716,270 | +5.7% | 5.72% | -17.0% |
Q2 2020 | $486,413,000 | +22.8% | 8,249,873 | -1.5% | 6.88% | -10.4% |
Q1 2020 | $396,189,000 | -22.2% | 8,379,642 | -0.6% | 7.68% | -4.9% |
Q4 2019 | $509,366,000 | +2.2% | 8,431,820 | +1.3% | 8.08% | -12.9% |
Q3 2019 | $498,566,000 | -2.5% | 8,321,914 | +4.6% | 9.27% | +6.2% |
Q2 2019 | $511,404,000 | +1981.8% | 7,957,128 | +2529.2% | 8.73% | +545.9% |
Q1 2019 | $24,566,000 | +18.8% | 302,643 | -20.9% | 1.35% | -0.6% |
Q4 2018 | $20,683,000 | +29.1% | 382,588 | +23.2% | 1.36% | +33.9% |
Q3 2018 | $16,017,000 | +19.2% | 310,536 | -3.7% | 1.02% | -11.3% |
Q2 2018 | $13,442,000 | -2.3% | 322,586 | +3.3% | 1.15% | -15.9% |
Q1 2018 | $13,761,000 | +6.6% | 312,186 | +21.6% | 1.36% | +1.1% |
Q4 2017 | $12,908,000 | -4.2% | 256,706 | -3.4% | 1.35% | -4.3% |
Q3 2017 | $13,469,000 | +17.9% | 265,706 | +18.3% | 1.41% | +4.3% |
Q2 2017 | $11,423,000 | +38.4% | 224,562 | +9.4% | 1.35% | +22.8% |
Q1 2017 | $8,251,000 | +89.5% | 205,253 | +125.6% | 1.10% | +23.5% |
Q4 2016 | $4,353,000 | +10.0% | 91,000 | -15.7% | 0.89% | +24.6% |
Q3 2016 | $3,957,000 | +57.3% | 108,000 | 0.0% | 0.72% | +51.2% |
Q2 2016 | $2,515,000 | -55.0% | 108,000 | -21.7% | 0.47% | -53.4% |
Q1 2016 | $5,589,000 | – | 138,000 | – | 1.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tweedy, Browne Co LLC | 3,510,173 | $159,221,447 | 8.52% |
Bellevue Group AG | 9,233,700 | $418,840,632 | 6.75% |
Deep Track Capital, LP | 2,834,069 | $128,553,370 | 4.96% |
BVF INC/IL | 4,004,613 | $181,649,246 | 4.90% |
Sicart Associates LLC | 203,132 | $9,214,068 | 3.61% |
Camber Capital Management LP | 2,250,000 | $102,060 | 3.36% |
Privium Fund Management B.V. | 228,493 | $10,364,443 | 3.08% |
Orbimed Advisors | 2,169,500 | $98,408,520 | 2.09% |
SECTOR GAMMA AS | 165,616 | $7,512,342 | 1.92% |
TANAKA CAPITAL MANAGEMENT INC | 14,612 | $663 | 1.89% |